Status:
COMPLETED
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 ...
Detailed Description
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg fo...
Eligibility Criteria
Inclusion
- Diagnosis of perennial allergic rhinitis (PAR).
- Must comply with study procedures and be literate.
Exclusion
- Significant concomitant medical conditions.
- Use of corticosteroids.
- Use of allergy and other identified medications during the study.
- Current tobacco use or tobacco use within the past year.
- Exposure to an investigational study drug within the past 12 months.
- Clinically significant abnormal electrocardiograms (ECG) or laboratory abnormality.
Key Trial Info
Start Date :
February 7 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 4 2006
Estimated Enrollment :
301 Patients enrolled
Trial Details
Trial ID
NCT00289198
Start Date
February 7 2006
End Date
July 4 2006
Last Update
April 13 2018
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Diego, California, United States, 92123
2
GSK Investigational Site
Baltimore, Maryland, United States, 21236
3
GSK Investigational Site
Wheaton, Maryland, United States, 20902
4
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747